Wilmington, Delaware, United States, June 06, 2023 (GLOBE NEWSWIRE) -- The market value of fecal immunochemical diagnostic tests (FITs) is expected to reach US$ 2.1 billion by 2031. Between 2023 and ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

A brief research report compared screening costs per early-detected colorectal cancer (CRC) case among fecal immunochemical tests (FIT), multitarget stool DNA tests (MSDT) and next-generation MSDTs (N ...

Annual FIT-based screening produced fewer CRC cases, fewer CRC deaths and more life years gained versus all other strategies, even at real-world adherence rates. Every screening strategy that was ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas Imperiale, M.D., has ...